Stonerise Capital Management LLC maintained its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,000 shares of the medical equipment provider’s stock at the close of the second quarter. Zimmer Biomet Holdings makes up 5.9% of Stonerise Capital Management LLC’s investment portfolio, making the stock its 7th biggest holding. Stonerise Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $3,210,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in ZBH. BlackRock Inc. increased its stake in Zimmer Biomet Holdings by 4,042.4% in the 1st quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock valued at $2,044,168,000 after buying an additional 16,336,262 shares during the period. JPMorgan Chase & Co. increased its stake in Zimmer Biomet Holdings by 92.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock valued at $421,146,000 after buying an additional 1,577,874 shares during the period. Harbour Capital Advisors LLC increased its stake in Zimmer Biomet Holdings by 13,131.3% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock valued at $10,145,000 after buying an additional 1,292,773 shares during the period. Nordea Investment Management AB increased its stake in Zimmer Biomet Holdings by 25.0% in the 1st quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock valued at $602,159,000 after buying an additional 987,398 shares during the period. Finally, Glenview Capital Management LLC acquired a new position in Zimmer Biomet Holdings in the 1st quarter valued at approximately $94,197,000. Hedge funds and other institutional investors own 85.35% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/20/stonerise-capital-management-llc-continues-to-hold-stake-in-zimmer-biomet-holdings-inc-zbh.html.
Several research analysts have weighed in on ZBH shares. ValuEngine lowered shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Citigroup Inc. upped their price objective on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, June 9th. Royal Bank Of Canada upped their price objective on shares of Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research note on Wednesday, June 21st. Cantor Fitzgerald started coverage on shares of Zimmer Biomet Holdings in a research note on Thursday, June 29th. They issued a “neutral” rating and a $137.00 price objective on the stock. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $148.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, June 30th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $136.75.
Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded up 0.81% on Wednesday, reaching $116.42. 235,750 shares of the company were exchanged. The stock has a 50 day moving average of $114.50 and a 200 day moving average of $120.75. The firm has a market capitalization of $23.54 billion, a PE ratio of 33.16 and a beta of 1.21. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by ($0.02). The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. Zimmer Biomet Holdings’s quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. Zimmer Biomet Holdings’s payout ratio is 27.59%.
In related news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.07% of the stock is currently owned by insiders.
Zimmer Biomet Holdings Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.